Evaluación de FebriDx® para el manejo de niños con infección respiratoria aguda febril

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES Enfermedades infecciosas y microbiologia clinica Pub Date : 2024-06-01 DOI:10.1016/j.eimc.2024.01.009

Paula de la Matta Farrando , Maria Teresa Suay Torres , Anna Sabater Sabaté , Victoria Trenchs Sainz de la Maza , Carles Luaces Cubells , Susanna Hernández Bou

{"title":"Evaluación de FebriDx® para el manejo de niños con infección respiratoria aguda febril","authors":"Paula de la Matta Farrando , Maria Teresa Suay Torres , Anna Sabater Sabaté , Victoria Trenchs Sainz de la Maza , Carles Luaces Cubells , Susanna Hernández Bou","doi":"10.1016/j.eimc.2024.01.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Acute respiratory infections (ARI) are a common cause of inappropriate antibiotic prescription (ATB) in pediatrics. FebriDx® is a rapid diagnostic test that differentiates between viral and bacterial infections. The objective is to analyse the impact of FebriDx® on ATB prescription when managing febrile ARI.</p></div><div><h3>Methods</h3><p>Prospective study carried out in patients aged 1-<18 years with febrile ARI in the emergency department. FebriDx® was performed and the impact on management was evaluated at follow-up.</p></div><div><h3>Results</h3><p>A total of 216 patients were included. Clinical assessment and FebriDx® result coincided in 174 (80.5%) cases. A modification of the initial therapeutic plan was made in 22 (52.4%) of the 42 discordant ones (10.2% of the overall patients). In pneumonia the impact was 34.5%; in all cases it involved not prescribing ATB.</p></div><div><h3>Conclusion</h3><p>FebriDx® could be a useful tool in the management of pediatric patients with febrile ARI to optimize ATB prescription.</p></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"42 6","pages":"Pages 313-316"},"PeriodicalIF":2.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213005X24001988","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Acute respiratory infections (ARI) are a common cause of inappropriate antibiotic prescription (ATB) in pediatrics. FebriDx® is a rapid diagnostic test that differentiates between viral and bacterial infections. The objective is to analyse the impact of FebriDx® on ATB prescription when managing febrile ARI.

Methods

Prospective study carried out in patients aged 1-< 18 years with febrile ARI in the emergency department. FebriDx® was performed and the impact on management was evaluated at follow-up.

Results

A total of 216 patients were included. Clinical assessment and FebriDx® result coincided in 174 (80.5%) cases. A modification of the initial therapeutic plan was made in 22 (52.4%) of the 42 discordant ones (10.2% of the overall patients). In pneumonia the impact was 34.5%; in all cases it involved not prescribing ATB.

Conclusion

FebriDx® could be a useful tool in the management of pediatric patients with febrile ARI to optimize ATB prescription.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对FebriDx®治疗发热性急性呼吸道感染患儿的评估

急性呼吸道感染（ARI）是儿科不当使用抗生素（ATB）的常见原因。FebriDx® 是一种能区分病毒和细菌感染的快速诊断测试。目的是分析它对发热性急性呼吸道感染患儿管理的影响。前瞻性研究针对急诊科 1-<18 岁发热 ARF 患者。进行了FebriDx®检查，并评估了其对ATB处方管理的影响。共纳入 216 名患者。174例（80.5%）患者的医疗指导与FebriDx®结果相符。在 42 例不一致的病例中，有 22 例（52.4%）（占患者总数的 10.2%）修改了最初的治疗方案。对肺炎的影响为 34.5%；在所有病例中，均涉及不开具 ATB。FebriDx®是治疗发热性ARF儿科患者的有效工具，可优化ATB处方。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Enfermedades infecciosas y microbiologia clinica 医学-传染病学

CiteScore

2.10

自引率

8.00%

发文量

194

审稿时长

29 days

期刊介绍： Hoy está universalmente reconocida la renovada y creciente importancia de la patología infecciosa: aparición de nuevos agentes patógenos, de cepas resistentes, de procesos con expresión clínica hasta ahora desconocida, de cuadros de una gran complejidad. Paralelamente, la Microbiología y la Infectología Clínicas han experimentado un gran desarrollo como respuesta al reto planteado por la actual patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica es la Publicación Oficial de la Sociedad Española SEIMC. Cumple con la garantía científica de esta Sociedad, la doble función de difundir trabajos de investigación, tanto clínicos como microbiológicos, referidos a la patología infecciosa, y contribuye a la formación continuada de los interesados en aquella patología mediante artículos orientados a ese fin y elaborados por autores de la mayor calificación invitados por la revista.